Cadrenal Secures FDA Alignment on Phase 3 Endpoint for CAD-1005 in HIT
CVKD is trading near its 52-week low of $1.49 (0.7% above the low).
Summary
Cadrenal announced positive FDA Type D meeting feedback aligning on the Phase 3 protocol and primary endpoint for CAD-1005 in HIT, with a projected $2 billion peak revenue opportunity.
Key Events · Product Development and Regulatory · CVKD
-
FDA Aligns on Phase 3 Endpoint
The FDA agreed on an optimized composite primary endpoint measuring adjudicated new or worsening thromboembolic events through Day 14 or hospital discharge in SRA+ HIT patients.
-
Placebo-Controlled Design Confirmed
The FDA agreed to placebo control with standard anticoagulation in both CAD-1005 and placebo arms, strengthening the registrational study design.
-
$2B Peak Revenue Projection
The company projects approximately $2 billion in peak annual revenue for CAD-1005 in HIT, targeting roughly 50,000 confirmed acute HIT diagnoses annually in the U.S.
-
Regulatory Path Forward
Positive Type D meeting feedback provides clarity on the Phase 3 protocol and Statistical Analysis Plan, with the company incorporating FDA recommendations.
Analysis · CVKD · Life Sciences
The FDA has agreed on the primary endpoint definition and placebo-controlled design for a Phase 3 registrational study of CAD-1005 in heparin-induced thrombocytopenia. This removes a major regulatory uncertainty for the lead asset and clears a path toward a pivotal trial. The company also disclosed a projected $2 billion peak annual revenue opportunity for the indication. Against a backdrop of a going-concern warning and cash runway only into October 2026, this regulatory clarity strengthens the asset's value proposition at a critical juncture.
How filings like this one have moved
In the 30 days to Sep 10, 2026, 35.7% of the 1872 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.01%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CVKD was trading at $1.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.5M. The 52-week trading range was $1.49 to $14.64. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.